BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers Sells 2,500 Shares

BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the business’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $17.94, for a total transaction of $44,850.00. Following the sale, the vice president now owns 19,884 shares of the company’s stock, valued at approximately $356,718.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

James Mathers also recently made the following trade(s):

  • On Thursday, July 11th, James Mathers sold 2,500 shares of BioLife Solutions stock. The shares were sold at an average price of $17.15, for a total transaction of $42,875.00.

BLFS stock traded down $0.03 during trading on Thursday, hitting $17.24. 138,656 shares of the company’s stock traded hands, compared to its average volume of 173,845. The company has a quick ratio of 12.99, a current ratio of 14.50 and a debt-to-equity ratio of 0.02. BioLife Solutions Inc has a 52 week low of $9.15 and a 52 week high of $26.35. The firm’s fifty day moving average price is $17.24. The stock has a market cap of $324.10 million, a PE ratio of 123.14 and a beta of 1.32.



BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. The business had revenue of $5.77 million during the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. As a group, equities analysts forecast that BioLife Solutions Inc will post 0.12 earnings per share for the current fiscal year.

Several analysts have weighed in on the stock. BidaskClub upgraded shares of Xilinx from a “hold” rating to a “buy” rating in a research note on Saturday, June 29th. ValuEngine upgraded shares of XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday. Maxim Group set a $24.00 target price on shares of BioLife Solutions and gave the company a “buy” rating in a research note on Wednesday, May 22nd. Northland Securities boosted their target price on shares of Paycom Software from $215.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $17.80.

Several institutional investors have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC grew its position in shares of BioLife Solutions by 2.9% during the first quarter. Janney Montgomery Scott LLC now owns 21,115 shares of the medical equipment provider’s stock worth $378,000 after acquiring an additional 600 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock worth $166,000 after acquiring an additional 2,400 shares during the last quarter. Cadence Capital Management LLC grew its position in shares of BioLife Solutions by 1.8% during the first quarter. Cadence Capital Management LLC now owns 195,269 shares of the medical equipment provider’s stock worth $3,493,000 after acquiring an additional 3,439 shares during the last quarter. Cowen Prime Services LLC bought a new position in shares of BioLife Solutions during the first quarter worth about $63,000. Finally, WINTON GROUP Ltd grew its position in shares of BioLife Solutions by 26.3% during the second quarter. WINTON GROUP Ltd now owns 22,118 shares of the medical equipment provider’s stock worth $375,000 after acquiring an additional 4,607 shares during the last quarter. Institutional investors and hedge funds own 45.76% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Article: Trade Deficit

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.